Pernix Therapeutics (PTX) Hits New 52-Week Low at $0.78

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) reached a new 52-week low on Thursday . The company traded as low as $0.78 and last traded at $0.81, with a volume of 600 shares changing hands. The stock had previously closed at $0.81.

Separately, ValuEngine upgraded Pernix Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, August 20th.

The company has a quick ratio of 0.71, a current ratio of 0.77 and a debt-to-equity ratio of -1.37.



Pernix Therapeutics (NASDAQ:PTX) last posted its quarterly earnings results on Thursday, August 9th. The specialty pharmaceutical company reported ($1.13) earnings per share for the quarter. The company had revenue of $21.09 million during the quarter.

About Pernix Therapeutics (NASDAQ:PTX)

Pernix Therapeutics Holdings, Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry.

See Also: Outstanding Shares and The Effect on Share Price

Receive News & Ratings for Pernix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply